Credit: Roland Magnusson/Shutterstock.com Covington Defeats Jones Day: AstraZeneca Escapes $107.5M Verdict
AstraZeneca prevailed on its argument that patents-in-suit are invalid because they are not enabled on the issue of unit dosage.
August 15, 2024 at 05:34 PM
4 minute read
Patent Litigation
The original version of this story was published on Texas Lawyer
What You Need to Know
- AstraZeneca was able to vacate a jury verdict of $107.5 million on final judgment in a patent infringement case.
- Wyeth alleged one of AstraZeneca's most successful anticancer drugs infringed on two of its patents.
- On final judgment, a Delaware federal district judge held that Wyeth patents were invalid.
AstraZeneca Pharmaceuticals LP, arguing posttrial against a jury finding that two of plaintiffs' patents were valid, got an opposite finding, erasing a $107.5 million verdict.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1Ex-Prosecutor and Judge Fatally Shot During Attempted Arrest on Federal Corruption Charges
- 2'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 3The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 4NYC Mayor Eric Adams Indicted on Public Corruption Allegations
- 5What We Know About the Kentucky Judge Killed in His Chambers
